HROW

Analyst Note: Harrow Health, Inc. (HROW)

Date: 2026-06-13 Current Price: $42.87

1. Structural Readiness

• Aggressive/Pre-Breakout Entry: Not recommended for conservative capital; currently a "watch" state.
• Breakout Level: Pending confirmation.
• Current Price: $42.87.
• Extension: Not applicable (price is within the forming range, not extended above the breakout).
• ATR Context: Current ATR is 5.0% (High). This indicates elevated volatility, which is consistent with a "forming" phase in a growth name where market participants are weighing new product launches and guidance.

2. Thesis Layer

• Thesis Classification: Tactical / Setup-Led.
• Analysis: As of 2026-06-13, there is no named secular thesis attached to this specific setup in the current context. The investment case is not driven by a broad macro theme (e.g., "AI in Healthcare" or "Global Aging") but is strictly a function of the company's specific operational execution and the technical setup quality.
• Judgment Criteria: The conviction must be derived entirely from the quality of the setup (structural integrity, volatility profile) and the fundamental business fundamentals (revenue growth, product mix, guidance adherence). No external macro narrative should be invented to support the position.

3. Business Overview

Harrow Health, Inc. is a leading ophthalmic pharmaceutical company engaged in the discovery, development, and commercialization of innovative eye care products for the U.S. market. The business model is a hybrid of commercialized branded products and a high-margin compounding business.

• Core Commercial Portfolio: The company owns one of the largest portfolios of branded ophthalmic pharmaceuticals in the U.S. Key products include:
• VEVYE: A dry eye treatment that has surpassed XIIDRA in total prescriptions as of March 2026. In Q1 2026, VEVYE generated $20.9 million in revenue. The dry eye category has grown 20% year-over-year in prescription volume for two consecutive years, with VEVYE being the only branded product to grow in Q1.
• IHEEZO: Contributed $1.9 million in Q1 2026. Management noted an approximate 20% to 25% improvement in net pricing and the introduction of multiunit packaging in Q3.
• Other Portfolios: The specialty and TRIESENCE portfolio delivered $7.8 million, and Access+ revenue was $13.5 million.
• ImprimisRx: The company owns and operates ImprimisRx, a leading ophthalmology-focused pharmaceutical-compounding business. It maintains a formulary of over 30 compounded formulations and serves a customer base of more than 10,000 U.S. eyecare-dedicated prescribers and institutions.
• Pipeline & Future Launches (Management Expectations):
• BYOOVIZ & BYQLOVI: Management expects to commercially launch both products in mid-2026.
• OPUVIZ: Expected commercial launch in mid-2027.
• MELT-300: Following completion of studies, management expects to submit an NDA in the first half of 2027, with a potential commercial launch in the second half of 2028 if approved.
• Financial Guidance (Source: Earnings Transcript, 2026-05-12):
• Full Year 2026: Reaffirmed revenue guidance of $350 million to $365 million.
• Q2 2026: Expected total revenues in the range of $71 million to $81 million.
• VEVYE Outlook: Expected to deliver sequential growth and exceed the $100 million revenue outlook for the year.
• Capital Structure & Obligations:
• In March 2026, the company issued $50 million in additional 8.625% Senior Notes due 2030.
• In February 2026, a one-time upfront payment of $4 million was made to Samsung Bioepis for a development and commercialization agreement.
• Contract manufacturing commitments for the year ending December 31, 2026, are approximately $10.7 million.

4. Archetype and Conviction

• Archetype: Growth Leader.
• *Fit:* The company demonstrates clear top-line growth (revenue guidance of $350M-$365M), successful commercialization of new assets (VEVYE surpassing competitors), and a robust pipeline of near-term launches (BYOOVIZ, BYQLOVI). The business model benefits from high-margin compounding (ImprimisRx) and branded pricing power.
• Valuation Context:
• Forward consensus EPS for FY1 is $0.2475, and FY2 is $2.30625. This suggests a significant earnings inflection is anticipated in the second year, likely driven by the full-year impact of the 2026 product launches and VEVYE's trajectory toward $100M.
• Conviction Stack:
• Thesis Strength: Moderate (Tactical, no macro tailwind).
• Evidence Quality: High. Multiple primary sources (earnings transcripts, SEC filings) confirm guidance, product performance, and pipeline timelines.
• Structural Quality: The setup is "Forming." The price is holding above support, but the breakout has not fired. The 5.0% ATR (High) suggests active trading interest but also elevated risk of whipsaw before a trend is established.
• Rerating Potential: High, contingent on the successful mid-2026 launches of BYOOVIZ and BYQLOVI and the continued dominance of VEVYE.
• Setup Readiness: The setup is not yet actionable for a conservative entry. It is a "partial" signal. The "Forming" state implies a ~69% historical probability of a breakout, but the trade is not complete until the price clears the resistance level.

5. Invalidations, Strengths, and Gaps

• Gaps in Evidence:
• Detailed Q2 Performance: While Q2 guidance is provided ($71M-$81M), actual Q2 results as of June 13 are not yet in the evidence block (the last earnings transcript is May 12).
• Competitor Reaction: No specific data on competitor pricing responses to VEVYE's growth is available in the provided evidence.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: VEVYE surpassed XIIDRA in prescriptions and is on track for $100M revenue; Management reaffirmed $350M-$365M FY2026 guidance; Two major new products (BYOOVIZ, BYQLOVI) expected to launch mid-2026. Key risks: Setup is "Forming" with no confirmed breakout; High ATR (5.0%) indicates elevated volatility and potential for false moves; Execution risk on mid-2026 product launches; Debt load increased with $50M new notes issuance. Expected horizon: 3 to 6 months for the setup to resolve (breakout or invalidation) and for mid-2026 product launches to impact financials.